Using the anti‐LGALS3BP therapeutic antibody named 1959 [30], we demonstrated that intact LGALS3BP+ EVs released by GBM cells can be detected and LGALS3BP amount quantified by a sandwich ELISA assay (Fig. 2C). This evidence concerns the gene LGALS3BP and glioblastoma.